Compositions and method of treatment for improving circulatory performance

Claim 2

A therapeutic positive inotropic composition for increasing contractility of the heart as shown by a positive inotropic effect which comprises a biologically acceptable carrier and in an amount effective to cause a positive inotropic effect, a cardiac glycoside selected from the group consisting of ouabain, digoxin, digitoxin, deslanoside and digitalis and a protoberberine alkaloid selected from the group consisting of berberine, discretine, xylopinine, berberrubine, tetrahydropalmatine and stepharotine and the pharmaceutically acceptable salts thereof, the composition being effective to cause such a positive inotropic effect.

Claim 3

The therapeutic composition of claim 1, wherein the protoberberine alkaloid is berberine.

Claim 4

The therapeutic composition of claim 2, wherein the cardiac glycoside is ouabain.

Claim 5

The therapeutic composition of claim 2, wherein the cardiac glycoside is digoxin.

Claim 6

The therapeutic composition of claim 2, wherein the cardiac glycoside is digitoxin.

Claim 7

The therapeutic composition of claim 2, wherein the cardiac glycoside is deslanoside.

Claim 8

The therapeutic composition of claim 2, wherein the cardiac glycoside is digitalis.

Claim 9

A therapeutic method of increasing contractility of the mammalian heart as shown by a positive inotropic effect which comprises administering to a mammal in need thereof in an amount effective to cause a positive inotropic effect, a composition which comprises a biologically acceptable carrier and a protoberberine alkaloid selected from the group consisting of discretine, xylopinine and stepharotine and the pharmaceutically acceptable salts thereof, in conjunction with a cardiac glycoside selected from the group consisting of ouabain, digoxin, digitoxin, deslanoside and digitalis, causing a positive inotropic effect over a wider therapeutic index than by administration of the cardiac glycoside alone.

Claim 10

A therapeutic method of increasing contractility of the mammalian heart as shown by a positive inotropic effect which comprises administering to a mammal in need thereof in an amount effective to cause a positive inotropic effect, a composition which comprises a biologically acceptable carrier and a protoberberine alkaloid selected from the group consisting of discretine, xylopinine and stepharotine and the pharmaceutically acceptable salts thereof, in conjunction with a cardiac glycoside selected from the group consisting of ouabain, digoxin, digitoxin, deslanoside and digitalis, causing a positive inotropic effect over a wider therapeutic index than by administration of the cardiac glycoside alone.

Claim 11

The therapeutic method of claim 8, wherein the protoberberine alkaloid is administered intravenously.

Claim 12

The therapeutic method of claim 8, wherein the cardiac glycoside is ouabain.

Claim 13

The therapeutic method of claim 8, wherein the cardiac glycoside is digoxin.

Claim 14

The therapeutic method of claim 8, wherein the cardiac glycoside is digitoxin.

Claim 15

The therapeutic method of claim 8, wherein the cardiac glycoside is deslanoside.

Claim 16

The therapeutic method of claim 8, wherein the cardiac glycoside is digitalis.

Claim 17

The therapeutic method of 8, wherein the cardiac glycoside and the protoberberine alkaloid are administered periodically.

Claim 18

The therapeutic method of 8, wherein the cardiac glycoside and the protoberberine alkaloid are administered periodically.

Claim 19

The therapeutic method of claim 8, wherein the protoberberine alkaloid is administered in a dosage in the range of about 0.001 to about 0.2 mg/kg per day.

Claim 20

The therapeutic method of claim 8, further comprising discontinuing the administration.